Bioassets Development Corporation

BioAssets Development Corporation, a biopharmaceutical company, develops spine indications for biologic drugs. It focuses on the development of a tumor necrosis factor alpha (TNF) inhibitor therapy to treat the underlying cause of pain in sciatica. It markets tumor necrosis factor alpha (TNF) inhibitors, which include monoclonal antibodies, infliximab or adalimumab, TNF-receptor fusion protein etanercept, and biologic drugs for the treatment of inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis. The company’s lead program also tests the potential of TNF inhibitors to treat pain and prevent nerve damage in patients with spinal disorders by treating the neuro-inflammatory disease mechanism. BioAssets Development Corporation was founded in 2005 and is based in Wellesley, Massachusetts. As of November 19, 2010, BioAssets Development Corporation operates as a subsidiary of Cephalon Inc.

show less